Posts Tagged ‘PARTNER’

RSS

June 10th, 2011

TAVR: A Stroke of Genius or Bad Luck?

and

After presentations at the ACC and American Association for Thoracic Surgery 2011 meetings, the PARTNER A results are finally published. PARTNER A compared  transaortic valve replacement (TAVR, also known as TAVI) with surgical aortic valve replacement (AVR) in patients with aortic stenosis who were eligible for AVR but considered to be at high surgical risk . At 1-year […]


April 11th, 2011

PARTNER A: An Investigator’s View

CardioExchange welcomes Dr. Michael Mack to discuss the results of the PARTNER study of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (AVR) in patients with aortic stenosis, which were just released at the ACC meetings in New Orleans. Dr. Mack was one of the principal investigators in this and the recently published […]


March 30th, 2011

Choosing a PARTNER for Life: A or B?

and

What is TAVI? During Transcatheter Aortic Valve Implantation (TAVI), a bioprosthetic valve is inserted through a catheter and implanted within the native stenotic aortic valve. The self-expanding CoreValve (Medtronic) and balloon-mounted Edwards SAPIEN (Edwards Lifesciences) valve are approved in Europe and under investigation in the U.S. for TAVI and can be implanted via the transfemoral, subclavian, or transapical route. […]


January 12th, 2011

Maybe TAVI Is Not All It’s Cracked Up To Be

and

The PARTNER trial of transcatheter aortic valve implantation (TAVI) for severe aortic stenosis was among the hottest cardiology stories of 2010.  Now that the hype is receding, some are questioning whether TAVI is ready for prime time. In three letters to the Editor of the New England Journal of Medicine, our colleagues point out that the […]


September 23rd, 2010

Howdy, PARTNER!

, , and

CardioExchange welcomes Mike Mack and E. Murat Tuzcu, investigators for the PARTNER trial, an ongoing, randomized study of transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis at high surgical risk. The first reported findings, published in the New England Journal of Medicine, showed an impressive 20% absolute reduction in 12-month mortality with […]


September 20th, 2010

What Does Gregg Stone Most Want to See at TCT This Year?

CardioExchange asked Gregg Stone, Director of the Transcatheter Cardiovascular Therapeutics (TCT) 2010 meeting, what he thinks will be the three most important trials or topics presented at this year’s conference. The most important and impactful trial is undoubtedly the PARTNER trial, which is a large randomized trial of transcatheter aortic valve implantation compared to medical therapy […]